Skip to Content

StageZero Life Sciences Ltd GNWSF

Rating as of

Morningstar’s Analysis

Currency in USD
Is it the right time to buy or sell?
Find out with Morningstar Premium
Is it the right time to buy or sell?
Find out with Morningstar Premium

1-Star Price


5-Star Price


Economic Moat


About Quantitative Ratings

Morningstar Quantitative ratings for equities (denoted on this page by) are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies withratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating. Click here for more on how to use these ratings.

Company Profile

Business Description

StageZero Life Sciences Ltd is a Canadian company which is focused on developing and commercializing proprietary molecular diagnostic tests for early detection of diseases and personalized health management, with a primary focus on cancer-related indications. It develops a proprietary platform technology, the Sentinel Principle, to identify novel biomarkers from whole blood. The lead product of the company is ColonSentry which is a blood test to determine the patient's current risk of having colorectal cancer.

70 East Beaver Creek Road, Unit 30
Richmond Hill, ON, L4B 3B2, Canada
T +1 905 209-2030
Sector Healthcare
Industry Diagnostics & Research
Most Recent Earnings Sep 30, 2020
Fiscal Year End Dec 31, 2020
Stock Type
Employees 17